Bio-Rad (BIO) Form 4: 1,869 RSU shares vested; 950 disposed

Bio-Rad Laboratories (BIO) reported an insider equity event by its President & COO.

Rhea-AI Filing Summary

Bio-Rad Laboratories (BIO) reported an insider equity event by its President & COO. On 10/24/2025, 1,869 shares of Class A common stock were acquired at $0 upon the vesting of restricted stock units, followed by a disposition of 950 shares under code F at $339.75 per share. Following these transactions, 919 Class A shares are held directly.

The related RSU line shows 1,869 underlying shares delivered and 5,609 RSUs remaining outstanding. The RSUs vest over four years at 25% per year on the yearly anniversary of the grant.

Insights

Equity compensation analyst

Routine RSU vesting with share withholding; no open‑market sale indicated.

Bio-Rad reports a standard equity compensation event: 1,869 Class A shares issued at $0 from RSU vesting on 10/24/2025. A code M entry reflects settlement of RSUs into shares, consistent with the filing’s explanation.

A code F disposition of 950 shares at $339.75 occurred the same day, a method commonly used to cover obligations, without indicating an open‑market sale. Post‑event holdings show 919 non‑derivative shares and 5,609 RSUs remaining, with vesting at 25% annually over four years.

Insider Trade Summary

1,869 shares exercised/converted

Exercise 3 txns

Insider DiVincenzo Jonathan P.

Role President & COO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,869	$0.00	$0.00
Exercise	Bio-Rad A Common Stock	1,869	$0.00	$0.00
Exercise Price or Tax Liability	Bio-Rad A Common Stock	950	$339.75	$323K

Holdings After Transaction: Restricted Stock Units — 5,609 contracts (Direct); Bio-Rad A Common Stock — 919 shares (Direct)

Footnotes (3)

1. F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
2. F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
3. F3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BIO report on this Form 4?

Vesting of restricted stock units into 1,869 Class A shares on 10/24/2025, plus a 950-share disposition under code F at $339.75.

How many Bio-Rad (BIO) shares does the reporting person now hold?

The reporting person holds 919 shares of Class A common stock directly after the reported transactions.

How many RSUs remain after this transaction for BIO?

The filing lists 5,609 restricted stock units remaining beneficially owned following the reported transactions.

What does transaction code M signify in this context?

Code M indicates settlement of a derivative security; here, 1,869 RSUs converted into Class A shares at $0.

What does transaction code F indicate for the BIO Form 4?

Code F reflects a disposition of 950 shares at $339.75 per share to satisfy obligations via share delivery/withholding.

What is the RSU vesting schedule noted by BIO?

The RSUs vest over four years at 25% per year on the yearly anniversary of the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/28/2025 - 12:29 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DiVincenzo Jonathan P.

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & COO

3. Date of Earliest Transaction (Month/Day/Year)
10/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	10/24/2025		M		1,869(1)	A	$0	1,869	D
Bio-Rad A Common Stock	10/24/2025		F		950	D	$339.75	919	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(2)	10/24/2025		M			1,869	(3)	(3)	Bio-Rad A Common Stock	1,869	$0	5,609	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

Remarks:

	/s/ Jonathan P. DiVincenzo	10/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.